This project is confidential and SynAbs is not able to disclose the target antigen and the context of the project.
A high affinity mAb has been synthesized with success by SynAbs team and is now part of blockbusters molecules of our client.
"As a leading in-vitro diagnostic provider to the clinical laboratory market, IDS is compelled to continuously rely on strong preferred partners who commit to high quality standards. For a project involving the development of innovative immunoassays againt a particular steroid, SynAbs rapidly came to the conclusion that only rat-LOU species could deliver the expected outcomes. This small molecule project has become a huge success !"